Benzinga | Oct 1, 2021 08:15AM EDT

Precigen ActoBio Announces Additional Interim Data From Phase 1b/2a Study Of AG019 ActoBiotics

Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (NASDAQ:PGEN), today announced additional positive interim data from the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics(tm) for the treatment of recent-onset type 1 diabetes (T1D) (clinical trial identifier: NCT03751007, EudraCT 2017-002871-24). Results were presented in an oral presentation entitled, "AG019 ActoBiotics as monotherapy or in association with teplizumab in recent-onset type 1 diabetes was safe and demonstrated encouraging metabolic and immunological effects" at the European Association for the Study of Diabetes (EASD) 57th Annual Meeting by Chantal Mathieu, MD, PhD, Professor of Medicine at the Katholieke Universiteit Leuven, Belgium.